Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM)

NCT07813377 · tracked via the Priya Life Science Spain tracker

Sponsor

Fundacion Clinic per a la Recerca Biomédica

Phase

Observational

Started

2026-05-30

Last updated

2026-09-10

Condition(s) studied

Glial TumorsThrombosisPulmonary Embolism (Diagnosis)

Investigational drug(s) / intervention(s)

Thromboelastometry values: EXTEM CT, MCF, α-angle below the lower limit of normal. Measurement obtained after anesthetic induction. - PT, aPTT, fibrinogen, platelet count. - Thrombin generation. -

Thromboelastometry values: EXTEM CT, MCF, α-angle below the lower limit of normal. Measurement obtained after anesthetic induction. - PT, aPTT, fibrinogen, platelet count. - Thrombin generation. -: * Molecular markers: including Next-Generation Sequencing (Oncomine Comprehensive Assay v3 or Oncomine Precision Assay) when available. * MGMT promoter methylation status.

Study summary

The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent Exclusion Criteria: * Patients under 18 years of age. * Emergency surgery. * Patients receiving antiplatelet or anticoagulant treatment. * Patients with known hematologic diseases associated with coagulation abnormalities. Examples include: * Congenital or acquired platelet function disorders. * Congenital deficiency of protein C or protein S. * Deficiency of coagulation factors II, V, VII, X, XII. * Glanzmann thrombasthenia. * Hemophilia A, B, or C. * Idiopathic thrombocytopenic purpura (ITP). * von Willebrand disease (types I, II, and III). * Systemic diseases that cause significant coagulation time alterations: * Prothrombin time \< 60%. * Activated partial thromboplastin time (aPTT) \> 50 seconds. * Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy

Primary outcome measure(s)

Thromboembolic events — 3 months post-surgery
Any newly developed thrombotic event (or acute worsening of a previous one) occurring within: Pulmonary embolism, stroke, venous trombosis
Thromboembolic events — first postoperative month
Any thromboembolic events

Trial sites (1)

Facility	City	Region	Status
Hospital Clínic Barcelona	Barcelona	Spain	Recruiting

More Fundacion Clinic per a la Recerca Biomédica trials in Spain

Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy Active, not recruiting

Pharmacokinetic Characterization of Tartaric Acid in Humans Starting soon

Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g Active, not recruiting

Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy Recruiting

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients Starting soon

Other trials for the same condition

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome Active, not recruiting

Effectiveness of a Needle-free Connector With Anti-reflux Technology in Reducing Complications From Long Peripheral Venous Catheters in Hospitalised Adult Patients: Randomised Clinical Trial Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07813377 on ClinicalTrials.gov ↗ ← All trials in Spain